{"id":"NCT03357952","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma","officialTitle":"A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Subjects With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-11-16","primaryCompletion":"2018-10-24","completion":"2021-11-19","firstPosted":"2017-11-30","resultsPosted":"2019-11-12","lastUpdate":"2025-02-04"},"enrollment":10,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Daratumumab","otherNames":["JNJ-54767414"]},{"type":"DRUG","name":"JNJ-63723283","otherNames":[]}],"arms":[{"label":"Part 1: JNJ-63723283 + Daratumumab","type":"EXPERIMENTAL"},{"label":"Part 2 and Part 3: Daratumumab/ JNJ-63723283 + Daratumumab","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to assess the safety of the combination of JNJ-63723283 and daratumumab (Part 1); to compare the overall response rate (ORR) in participants treated with JNJ-63723283 in combination with daratumumab versus daratumumab alone (Part 2); and to compare progression-free survival (PFS) in participants treated with JNJ-63723283 in combination with daratumumab versus daratumumab alone (Part 3).","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAE) in Safety run-in Phase (Part 1)","timeFrame":"Up to 2 years","effectByArm":[{"arm":"Part 1: Daratumumab + JNJ-63723283","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":13,"countries":["Belgium","Israel","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":9},"commonTop":["Neutropenia","Thrombocytopenia","Anaemia","Nausea","Vomiting"]}}